Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Kesmalea Therapeutics | 2023 | Series A | $6.0M | London |
| BehaVR | 2022 | Series B | $13.0M | Elizabethtown |
| Xerion Healthcare | 2022 | Grant | Undisclosed | Thame |
| Nucleome Therapeutics | 2022 | Series A | $42.0M | Headington |
| BibliU | 2022 | Series B | $1.4M | London |
| Opsydia | 2022 | Series Unknown | $4.0M | Oxford |
| MiroBio | 2022 | Series B | $97.0M | Oxford |
| ORCA Computing | 2022 | Series A | $15.0M | London |
| Scenic Biotech | 2022 | Series A | $31.0M | Amsterdam |
| Alethiomics | 2021 | Seed | $8.0M | Headington |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | Kesmalea Therapeutics | Series A | $6.0M | London, United Kingdom |
| 77 | BehaVR | Series B | $13.0M | Elizabethtown, United States |
| 78 | Xerion Healthcare | Grant | Undisclosed | Thame, United Kingdom |
| 79 | Nucleome Therapeutics | Series A | $42.0M | Headington, United Kingdom |
| 80 | BibliU | Series B | $1.4M | London, United Kingdom |
| 81 | Opsydia | Series Unknown | $4.0M | Oxford, United Kingdom |
| 82 | MiroBio | Series B | $97.0M | Oxford, United Kingdom |
| 83 | ORCA Computing | Series A | $15.0M | London, United Kingdom |
| 84 | Scenic Biotech | Series A | $31.0M | Amsterdam, The Netherlands |
| 85 | Alethiomics | Seed | $8.0M | Headington, United Kingdom |
Kesmalea Therapeutics is a biotech startup focusing on the discovery of novel protein degraders.
BehaVR develops evidence-based, immersive, digital therapeutics for behavioral health using Virtual Reality.
Xerion Healthcare is the technology commercialization company of University of Oxford.
Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
BibliU provides colleges and universities with digital content management, automation, and an analytics platform.
Opsydia is set to disrupt a number of industries by its ability to create practically invisible structures inside transparent materials.
MiroBio is Harnessing the natural control mechanisms of the immune system.
ORCA Computing is building the first scalable and flexible quantum computer powered by photonics.
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors.
Alethiomics is a biotech company harnessing the power of single-cell multi-omic technology to discover & develop treatment for blood cancer.
Rey is a mental health and wellness company integrating immersive tools and digital interventions with teletherapy
Orbit Discovery is a peptide display company identifying potential peptide drugs for a range of chronic diseases.
Omega Crop offers crop modelling, crop management, and weather modelling solutions.
DJS Antibodies designs and discovers novel therapeutic monoclonal antibodies against GPCRs.
Refeyn is specialising in label-free single molecule imaging and mass measurement.
Base Genomics is an epigenetics company focusing on developing a blood test for early-stage cancer and minimal residual disease.
Argonaut Therapeutics is a precision therapeutics company that was established to develop epigenetically-acting drugs which target abnormal.
Making learning easier for everyone
Metaboards is an electronic company that provides ubiquitous power and data, by creating metamaterials.
Oxford University spin-out developing next-generation CSP and solar thermal storage technologies to decarbonise industrial heat processes
Developing SRD® technology for a low-power display of vivid colours that doesn’t look washed out in bright conditions
Circadian Therapeutics is a Pharmaceutical company.
Oxford Impedance Diagnostics researches, designs and will market diagnostic tests for the measurement of clinical bio markers.
OxStem is a drug discovery company.
Oxtex Limited, a medical device company, manufactures anisotropic self-inflating tissue expanders that is based on hydrogel technology.
Oxford Science Enterprises has invested in 100 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Oxford Science Enterprises's top investment sectors include Biotechnology, Health Care, Life Science, Therapeutics, Manufacturing. The firm invests across 37 different industry categories.
Among tracked funding rounds, MiroBio received $97.0M in a Series B round. Oxford Science Enterprises's total known invested capital is $1.3B.
Oxford Science Enterprises's average investment size is $20.4M across its portfolio of 100 companies.
Recent Oxford Science Enterprises portfolio additions include Kesmalea Therapeutics, BehaVR, Xerion Healthcare, Nucleome Therapeutics, BibliU. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors